Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.

Autor: Abubakar M; Department of Internal Medicine, Ameer-Ud-Din Medical College, 6 Birdwood Road, Jinnah Town, Lahore, 54000, Punjab, Pakistan. Muhammadabubakar2053@hotmail.com., Irfan U; Department of Internal Medicine, Deccan College of Medical Sciences, Hyderabad, India., Abdelkhalek A; Department of Internal Medicine, Zhejiang University, Zhejiang, China., Javed I; Department of Internal Medicine, Ameer-Ud-Din Medical College, 6 Birdwood Road, Jinnah Town, Lahore, 54000, Punjab, Pakistan., Khokhar MI; Department of Surgery, Gujranwala Medical College, Gujranwala, Pakistan., Shakil F; Department of Emergency Medicine, Mayo Hospital, Lahore, Pakistan., Raza S; Department of Anesthesia, Social Security Teaching Hospital, Lahore, Punjab, Pakistan., Salim SS; Department of Surgery, Holy Family Red Crescent Medical College Hospital, Dhaka, Bangladesh., Altaf MM; Department of Internal Medicine, Ameer-Ud-Din Medical College, 6 Birdwood Road, Jinnah Town, Lahore, 54000, Punjab, Pakistan., Habib R; Department of Internal Medicine and Emergency, Indus Hospital, Lahore, Pakistan., Ahmed S; Department of Internal Medicine, Ziauddin Medical College, Karachi, Pakistan., Ahmed F; Department of Internal Medicine, Ziauddin Medical College, Karachi, Pakistan.
Jazyk: angličtina
Zdroj: Journal of cardiovascular translational research [J Cardiovasc Transl Res] 2024 Dec; Vol. 17 (6), pp. 1258-1285. Date of Electronic Publication: 2024 Jul 12.
DOI: 10.1007/s12265-024-10540-8
Abstrakt: Coronary artery disease (CAD), acute coronary syndrome (ACS), and heart failure (HF) are major global health issues with high morbidity and mortality rates. Biomarkers like cardiac troponins (cTn) and natriuretic peptides (NPs) are crucial tools in cardiology, but numerous new biomarkers have emerged, proving increasingly valuable in CAD/ACS. These biomarkers are classified based on their mechanisms, such as fibrosis, metabolism, inflammation, and congestion. The integration of established and emerging biomarkers into clinical practice is an ongoing process, and recognizing their strengths and limitations is crucial for their accurate interpretation, incorporation into clinical settings, and improved management of CVD patients. We explored established biomarkers like cTn, NPs, and CRP, alongside newer biomarkers such as Apo-A1, IL-17E, IgA, Gal-3, sST2, GDF-15, MPO, H-FABP, Lp-PLA2, and ncRNAs; provided evidence of their utility in CAD/ACS diagnosis and prognosis; and empowered clinicians to confidently integrate these biomarkers into clinical practice based on solid evidence.
Competing Interests: Declarations. Ethical approval: Not applicable. Consent for Publication: Not applicable. Conflict of Interests: The authors declare that they have no conflict of interest.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: